INTRODUCTION

Immunoglobulin M (IgM) is the first immunoglobulin isotype expressed on immature B cells and the first antibody that is produced when foreign antigens are encountered. IgM is mainly distributed in serum and exists in pentamer form, comprising 5%-10% of the total serum Ig. Bactericidal, complement activation and agglutination effects are the key functions of IgM.

Selective IgM deficiency (SIgMD) has been reported in Western countries and is often associated with severe or recurrent infections, autoimmunity, allergies, and malignancies; SIgMD appears to be more common than originally realized.

The epidemiology and clinical features of selective immunoglobulin M deficiency: A single-center study in China

Jinyao Ni1 | Junwu Zhang2 | Qi Chen1 | Yanxia Chen3 | Jinlin Liu4

1Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2Department of Clinical Laboratory, Wenzhou Hospital of Traditional Chinese Medicine Affiliated to Zhejiang Chinese Medical University, Wenzhou, China
3Department of Rheumatology, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, China
4Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital, Hangzhou Medical College, Hangzhou, China

Correspondence
Yanxia Chen and Jinlin Liu, Department of Clinical Laboratory, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, 158 Shangtang Road, 310014 Hangzhou, China. Emails: 695882502@qq.com (YC); liujinlinhz@163.com (JL)

Funding information
Jinlin Liu was supported by Zhejiang Provincial Natural Science Fund (No: LY18H200002).

Abstract

Background: Selective immunoglobulin M deficiency (SIgMD) is a rare primary immunodeficiency that is frequently reported in Western countries. However, large epidemiological and clinical studies of SIgMD in China are still lacking. Herein, we describe a cohort of SIgMD subjects in a large tertiary university hospital in China.

Methods: A cross-sectional study included 139,668 participants at First Affiliated Hospital of Wenzhou Medical University from January 2014 to October 2018 was conducted. Individuals with a serum IgM level less than 0.3 g/L with normal levels of serum IgA and IgG were defined as having SIgMD.

Result: A total of 63 subjects met the criteria for SIgMD (63/139,668, 0.045%), with a male-to-female ratio of 0.85, aged from 19 to 99 years. The most common clinical manifestation was autoimmune disorders (38/63, 60.32%), while the second most common manifestation was infections (21/63, 33.33%). Neither allergies nor tumors were found among these 63 SIgMD subjects. Most importantly, there were 30 patients with systemic lupus erythematosus among these 63 SIgMD subjects, accounting for 47.62% of all SIgMD subjects.

Conclusion: To our knowledge, we describe here the first large single-center cohort of adult patients affected by SIgMD in China. The most common clinical manifestation was autoimmune disorders, specifically systemic lupus erythematosus.

KEYWORDS
autoimmune disease, infection, selective IgM deficiency, systemic lupus erythematosus
The European Society for Immunodeficiencies (ESID) registry defines primary SIgMD as a serum IgM level repeatedly below 2 standard deviations (SDs) from the mean level for age with normal levels of the serum IgA, IgG, and IgG subclasses; the absence of T-cell defects; normal vaccination responses; and the absence of causative external factors.5 When these criteria are completely fulfilled, this condition is referred to as “truly selective primary IgM deficiency” (true SIgMD). Importantly, Janssen reported that only 6 of 261 (2%) subjects described in the literature (261 subjects with primary decreased serum IgM in 46 papers) completely met the criteria for true SIgMD.6 Therefore, the current definition of SIgMD should be modified to be more inclusive rather than exclusive7; more simply, subjects with IgM levels less than 30 mg/dL should be regarded as IgM-deficient subjects.8

The clinical features of SIgMD subjects have been described in previous review studies.1,9 Among them, respiratory tract infections were the most common clinical symptoms, including upper and lower respiratory tract infections, such as chronic sinusitis, bronchitis, pneumonia, bronchiectasis, and recurrent otitis media.10 In adults with SIgMD, autoimmune diseases and allergies are also common manifestations.

To date, only two SIgMD cases have been reported in China,11 and no large studies have reported on the prevalence and clinical manifestations of SIgMD in Chinese populations. Therefore, we initiated this cross-sectional cohort study in a large tertiary university hospital in China by analyzing the laboratory and hospital information system databases.

### 2 | PATIENTS AND METHODS

This study was a retrospective investigation of 139,668 patients for whom immunoglobulin tests had been ordered in the First Affiliated Hospital of Wenzhou Medical University from January 2014 to October 2018; during that time, the Wenzhou district of Zhejiang Province had a population of 8.2 million people. The concentrations of IgA, IgM, and IgG were measured by nephelometry (Siemens BN II and Beckman Coulter IMMAGE 800). Briefly, patients who repeatedly (at least twice) had IgM levels less than 0.3 g/L were regarded as IgM-deficient subjects.8 Patients with low or high IgG and IgA serum levels were excluded. The presence of any other well-defined primary or secondary immunodeficiencies accompanied by decreased levels of IgM was considered a criterion for exclusion. Only the clinical manifestations of patients with persistent decreased serum IgM levels were reviewed in detail.8 This study was approved by the First Affiliated Hospital of Wenzhou Medical University Ethics Committee.

### 3 | RESULT

#### 3.1 | Sixty-three subjects were defined as having SIgMD among the 139,668 subjects

Among the 139,668 subjects, a total of 63 subjects (63/139,668, 0.045%) met the criteria for SIgMD, including 29 males and 34 females, aged from 19 to 99 years with a mean age of 52 years at patient admission (Figure 1, Table 1).
3.2 | Clinical manifestations of these 63 SlgMD subjects

Recurrent infections as the presenting manifestation occurred in more than 80% of the patients with SlgMD. However, in contrast to previous SlgMD studies, subjects in this cohort commonly presented with recurrent infections. In this study, the most common clinical manifestation at the time of patient admission was an autoimmune disorder (38/63, 60.32%). Most importantly, there were 30 patients with systemic lupus erythematosus (SLE) among these 63 SlgMD subjects, accounting for 47.62% of all SlgMD subjects (Table 2). Other autoimmune diseases found in the study population are listed in Table 2. Infectious diseases occurred in 21 adults (21/63, 33.33%), and these diseases are listed in Table 2. Because many patients showed more than one clinical feature after the discharge diagnosis, other diagnoses affecting the circulatory, motor, urinary, endocrine, respiratory, digestive, and nervous systems of these SlgMD subjects are included in Table 3. These patients also had a significant presence of hypertension (15.87%), atherosclerosis (12.70%), osteoporosis (17.46%), renal cysts (7.94%), diabetes (9.52%), and brain infarction (7.94%). Of note, no tumor cases were found among these 63 SlgMD subjects.

4 | DISCUSSION

IgM deficiency was first described in 1967, when two male children with fulminant meningococcal septicemia were found to have low levels of IgM. The same authors also found 11 patients with low IgM levels who presented with meningitis and pyelonephritis in a retrospective study of 3,000 hospitalized patients.12 In 2006, the largest study of 36 SlgMD and 17 other SlgMD subjects was published.1,9 Although decades have passed, the prevalence and clinical consequences of decreased serum IgM levels are not sufficiently known. To date, only small cohorts of IgM-deficient subjects have been described.5 A variety of clinical manifestations has been associated with decreased serum IgM levels, including severe or recurrent infections, autoimmunity, allergy, and malignancy.5 However, the exact prevalence and clinical manifestations of SlgMD still need to be investigated.

The ESID registry defines SlgMD as a serum IgM level repeatedly below 2 SDs from the mean level for age with normal levels of serum IgA, IgG, and IgG subclasses; the absence of T-cell defects; normal vaccination responses; and the absence of causative external factors. Unfortunately, this ESID registry definition subsequently led Janssen et al6 to report that only 6 of 261 patients (261 primary decreased serum IgM patients in 46 papers) documented in the literature completely fulfilled the defined criteria for true SlgMD. Moreover, Janssen et al also classified selective IgM deficiency as follows: (a) true SlgMD when patients met the ESID registry criteria, (b) possible SlgMD when patients did not completely fulfill the ESID registry criteria because data on vaccination response or IgG subclasses were not available, and (c) unclassified primary antibody deficiency when other IgG subclass deficiencies and/or impaired responses to vaccine were present; however, this dilemma could not be solved by this multicenter study.5,7 Therefore, SlgMD should be defined without the exclusion of IgG subclass deficiencies, alterations in the T-cell subset, or impaired responses to vaccine.7

Thus, in this study, patients who had IgM levels less than 0.3 g/L with normal IgG and IgA serum levels were regarded as IgM-deficient subjects as previously reported.8 Moreover, patients in whom serum IgM was determined only once or rose to normal or patients with other secondary SlgMDs were also excluded.5 Only patients in whom IgM was determined on repeat occasions (at least

---

**Table 1** Patient basic information of selective IgM deficiency

| Patient information                  |       |
|--------------------------------------|-------|
| No. of patients                      | 63    |
| Gender                               |       |
| Male                                 | 29    |
| Female                               | 34    |
| Age                                  | 52.08 ± 16.89 |
| Prevalence(detected more than twice) | 63/139 668 (0.045%) |
| Prevalence(detected only one)        | 325/139 668 (0.233%) |
| Prevalence(both one and more than twice) | 388/139 668 (0.278%) |

**Table 2** The common clinical manifestation of selective IgM deficiency

| Clinical manifestation                  | No. of patients (%) |
|-----------------------------------------|---------------------|
| Autoimmune disease                      | 38 (60.32%)         |
| Systemic lupus erythematosus            | 30 (47.62%)         |
| Sjogren syndrome                       | 4 (6.35)            |
| Rheumatic heart disease                 | 1 (1.59)            |
| Scleroderma                             | 1 (1.59)            |
| Psoriasis                               | 1 (1.59)            |
| Rheumatoid arthritis                    | 1 (1.59)            |
| Infection disease                       | 21 (33.33%)         |
| Chronic gastritis                       | 6 (9.52)            |
| Pulmonary infection                     | 4 (6.35)            |
| Herpes                                  | 3 (4.76)            |
| Upper respiratory tract infection       | 2 (3.17)            |
| Bronchial asthma                        | 2 (3.17)            |
| Tuberculosis                            | 1 (1.59)            |
| Epididymitis                            | 1 (1.59)            |
| Cholecystitis                           | 1 (1.59)            |
| Bronchiectasis with infection           | 1 (1.59)            |

*Many patients showed more than one clinical feature.*
twice) were included, further supporting the accurate description of these SIgMD subjects in this study.

The exact prevalence of primary SIgMD remains unknown. A community-based survey showed that the prevalence of primary SIgMD in children was 0.03%. Additionally, a prevalence of 0.07% in an allergy and clinical immunology clinic and 1.68% in an unselected community health screening was found. Furthermore, a prevalence of 6% was found in primary immunodeficiency patients. Recently, an Iranian blood transfusion center study showed that the prevalence of healthy blood donors was 0.37%.

Importantly, SLE among all autoimmune disorders was the most common clinical manifestation in this study. However, the current study is limited. At the time of IgM measurement, they may be on concomitant immunosuppressive medications, we cannot rule out the effect of concomitant immunosuppressive medications on the low IgM. Therefore, this may contribute to a spuriously high prevalence of SIgMD among SLE patients. Moreover, this retrospective study lacked long-term follow-up of these patients. We cannot determine the cause-effect relationship between SIgMD and these autoimmune diseases. In the literature, a statistical analysis of serum Ig levels in SLE patients first reported by Saiki showed a decrease in serum IgM that was closely related to the disease duration of SLE. Patients with a longer duration of SLE had more striking decreases in serum IgM levels. Fegurgur et al in 62 adult SIgMD patients observed a significantly higher rate (42%) of autoimmunity and autoimmune disease with predominance of Hashimoto’s thyroiditis and SLE. Chovancova et al in their 17 adult patients with SIgMD reported four patients with SLE and five additional patients with positive ANA without a diagnosis of SLE. However, it is still difficult to elucidate how strong these associations are and if these immunopathological conditions are primary or secondary. Furthermore, whether the concomitant immunosuppressive agents could specifically decrease IgM without affecting the IgG and IgA in SLE patients is still need to be investigated.

### TABLE 3 The other clinical manifestation of selective IgM deficiency

| Clinical Manifestation | No. of patients (%) |
|------------------------|---------------------|
| Circulatory system     | 33 (52.38)          |
| Hypertension           | 10 (15.87)          |
| Atherosclerosis        | 8 (12.70)           |
| Arrhythmia             | 3 (4.76)            |
| Hyperlipidemia         | 3 (4.76)            |
| Thrombocytopenia       | 2 (3.17)            |
| Lymphocytosis          | 1 (1.59)            |
| Leukopenia             | 1 (1.59)            |
| Heart dysfunction      | 1 (1.59)            |
| Paroxysmal ventricular tachycardia | 1 (1.59) |
| Varicose veins of lower extremities | 1 (1.59) |
| Abdominal aortic aneurysm | 1 (1.59) |
| Pulmonary hypertension | 1 (1.59)            |
| Urinary system         | 12 (19.05)          |
| Renal cyst             | 5 (7.94)            |
| Benign prostatic hyperplasia | 3 (4.76) |
| Kidney stones          | 2 (3.17)            |
| Renal allergic purpura | 1 (1.59)            |
| Abnormal renal function| 1 (1.59)            |
| Endocrine system       | 10 (15.87)          |
| Diabetes               | 6 (9.52)            |
| Thyroid dysfunction    | 3 (4.76)            |
| Nodular goiter         | 1 (1.59)            |
| Respiratory system     | 9 (14.29)           |
| Respiratory failure    | 4 (6.35)            |
| Chronic obstructive pulmonary disease | 3 (4.76) |
| Interstitial lung disease | 1 (1.59) |
| Epistaxis              | 1 (1.59)            |
| Digestive system       | 9 (14.29)           |
| Oral ulcer             | 1 (1.59)            |
| Duodenal ulcer         | 1 (1.59)            |
| Gastrointestinal bleeding | 1 (1.59) |
| Intestinal dysfunction | 1 (1.59)            |
| Multiple colonic polyps| 1 (1.59)            |
| Liver nodules          | 1 (1.59)            |
| Hepatitis B virus      | 1 (1.59)            |
| Abnormal liver function| 1 (1.59)            |
| Cholelithiasis         | 1 (1.59)            |

### TABLE 3 (Continued)

| Clinical Manifestation | No. of patients (%) |
|------------------------|---------------------|
| Nervous system         | 8 (12.70)           |
| Brain infarction       | 5 (7.94)            |
| Metabolic encephalopathy | 1 (1.59) |
| Optic neuritis         | 1 (1.59)            |
| Parkinson’s Disease    | 1 (1.59)            |
| Immune system          | 1 (1.59)            |
| Splenomegaly           | 1 (1.59)            |
| Physical examination   | 6 (9.52)            |
| Solar dermatitis       | 1 (1.59)            |
| Inguinal hernia        | 1 (1.59)            |
| Hand Tinea             | 1 (1.59)            |

*Many patients showed more than one clinical feature.*
Furthermore, Boes revealed that compared with regular lupus-prone lymphoproliferative (lpr) mice, lpr mice that lacked secreted IgM developed increasing levels of IgG autoantibodies to double-stranded DNA and had more abundant deposits of immune complexes in the kidney. Similarly, Ehrenstein et al demonstrated that mice deficient in serum IgM were prone to spontaneous autoimmunity, as evidenced by the development of anti-DNA antibodies and the renal deposition of IgG. More recently, Nguyen revealed that natural IgM could prevent autoimmunity through the induction of B-cell central tolerance and highlighted that polyclonal IgM can rescue B-cell development and reduce autoantibody levels. Therefore, all these reports could partly support the strong association between the SLE and SlgMD. Due to the possible immunomodulatory effects and antimicrobial effects of IgM, highly enriched IgM preparations may be the most desirable therapeutic modality for SlgMD.

Additionally, the second most frequent clinical manifestation was infectious diseases, with recurrent infections as the presenting manifestation occurring in more than 80% of patients with SlgMD. However, in contrast to previous studies in which SlgMD subjects commonly presented with recurrent infections, our study reported significantly fewer patients presenting with recurrent infections. Importantly, the clinical manifestations were recorded at the time of discharge in this study, and long-term follow-up may help to determine the true incidence of recurrent infection in these SlgMD subjects. Moreover, SLE patients prone to infection were not included in the analysis of infection rate, which may further contribute to the lower incidence of infectious diseases in this study.

The prevalence of allergic disorders in individuals with SlgMD is estimated to be 25%-33% in Western countries. However, only two patients with bronchial asthma were found among these 63 SlgMD subjects. In contrast to Western countries, the demand for specialists and consultants in allergy and clinical immunology in China is still lagging behind the number of patients suffering from allergies or immunodeficiency, which may contribute to this low incidence. Additionally, nearly half of the SlgMD subjects in our study were 50 years of age or older, and most of them had underlying common diseases, including hypertension, atherosclerosis, osteoporosis, renal cysts, or diabetes. Whether these common diseases are associated with SlgMD still needs to be investigated. Thus, from this study, we concluded that SlgMD is likely a heterogeneous disorder. More attention should be paid to autoimmune disease, especially SLE, in these patients.

Acknowledgments
The authors would like to thank all of the members of the Department of Clinical Laboratory (Zhejiang Provincial People’s Hospital, Hangzhou, China) for their assistance and encouragement.

ORCID
Junwu Zhang https://orcid.org/0000-0002-8536-2080
Jinlin Liu https://orcid.org/0000-0003-0502-4813

References
1. Chovanova Z, Kralickova P, Pejchalova A, et al. Selective IgM deficiency: clinical and laboratory features of 17 patients and a review of the literature. J Clin Immunol. 2017;37(6):559-574.
2. Zhang Y, Garcia-Ibanez L, Toellner KM. Regulation of germinal center B-cell differentiation. Immunol Rev. 2016;270(1):8-19.
3. Liu J, Wang Y, Xiong E, et al. Role of the IgM Fc receptor in immunity and tolerance. Front Immunol. 2019;10:529.
4. Louis AG, Gupta S. Primary selective IgM deficiency: an ignored immunodeficiency. Clin Rev Allergy Immunol. 2014;46(2):104-111.
5. Janssen LMA, van Hout R, de Vries E. Challenges in investigating patients with isolated decreased serum IgM: the SiMcal study. Scand J Immunol. 2019;89(6):e12763.
6. Janssen LMA, Macken T, Creemers M, Pruit JJ, Eijk JJ, de Vries E. Truly selective primary IgM deficiency is probably very rare. Clin Exp Immunol. 2018;191(2):203-211.
7. Gupta S, Gupta A. Defining primary selective IgM deficiency. J Clin Immunol. 2019;39(4):350-352.
8. Entezari N, Adab Z, Zeydi M, et al. The prevalence of selective immunoglobulin M deficiency (SlgMD) in Iranian volunteer blood donors. Hum Immunol. 2016;77(1):7-11.
9. Goldstein MF, Goldstein AL, Dunskey EH, Dvorin DJ, Bealech NA, Shamir K. Selective IgM immunodeficiency: retrospective analysis of 36 adult patients with review of the literature. Ann Allergy Asthma Immunol. 2006;97(6):717-730.
10. Gupta S, Gupta A. Selective IgM deficiency-an underestimated primary immunodeficiency. Front Immunol. 2017;8:1056.
11. Zhao SY, Jiao AX, Zhang GF. Selective IgM deficiency in 2 children. Zhonghua Er Ke Za Zhi. 2007;45(11):871.
12. Hobbs JR, Milner RD, Watt PJ. Gamma-M deficiency predisposing to meningococcal septicaemia. Br Med J. 1967;4(5579):583-586.
13. Cassidy JT, Nordby GL. Human serum immunoglobulin concentrations: prevalence of immunoglobulin deficiencies. J Allergy Clin Immunol. 1975;55(1):35-48.
14. Boes M, Schmidt T, Linkemann K, Beaudette BC, Marshak-Rothstein A, Chen J. Accelerated development of IgG autoantibodies and autoimmune disease in the absence of secreted IgM. Proc Natl Acad Sci U S A. 2000;97(3):1184-1189.
15. Saiki O, Saeki Y, Tanaka T, et al. Development of selective IgM deficiency in systemic lupus erythematosus patients with disease of long duration. Arthritis Rheum. 1997;40(11):1289-1292.
16. Lucub-Feurgur D, Gupta S. Comprehensive clinical and immunological features of 62 adult patients with selective primary IgM deficiency. Am J Clin Exp Immunol. 2019;8(6):55-67.
17. Ehrenstein MR, Cook HT, Neuberger MS. Deficiency in serum immunoglobulin (Ig)M predisposes to development of IgG autoantibodies. J Exp Med. 2000;191(7):1253-1258.
18. Nguyen TT, Elsner RA, Baumgarth N. Natural IgM prevents autoimmunity by enforcing B cell central tolerance induction. J Immunol. 2015;194(4):1489-1502.
19. Jung JY, SuH CH. Infection in systemic lupus erythematosus, similarities, and differences with lupus flare. Korean J Intern Med. 2017;32(3):429-438.
20. Yel L, Ramanuja S, Gupta S. Clinical and immunological features in IgM deficiency. Int Arch Allergy Immunol. 2009;150(3):291-298.
21. Wong GKW, Li J, Bao YX, et al. Pediatric allergy and immunology in China. Pediatr Allergy Immunol. 2018;29(2):127-132.

How to cite this article: Ni J, Zhang J, Chen Q, Chen Y, Liu J. The epidemiology and clinical features of selective immunoglobulin M deficiency: A single-center study in China. J Clin Lab Anal. 2020;34:e23289. https://doi.org/10.1002/jcla.23289